The efficacy of imiquimod 5% cream (Aldara) in the treatment of aural plaque in horses: a pilot open-label clinical trial

Loading...
Thumbnail Image

View/Download File

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

The efficacy of imiquimod 5% cream (Aldara) in the treatment of aural plaque in horses: a pilot open-label clinical trial

Published Date

2010

Publisher

Veterinary Dermatology

Type

Article

Abstract

Aural plaques affect at least 22% of horses and can be asymptomatic or cause ear sensitivity. Immunohistochemical and electron microscopy studies have shown a strong association between aural plaques and papilloma virus. The purpose of this study was to investigate the efficacy of imiquimod 5% cream, an immune response modifier with potent antiviral activity, in the treatment of equine aural plaques. Twenty-one horses were enrolled and 16 completed the study. Imiquimod 5% cream was applied three times a week, every other week. When both ears were affected only the worst affected ear was treated. Adverse effects in all horses included marked local inflammation, exudation and thick crust formation at the site of treatment and the adjacent skin. Removal of the crust before treatment was painful and required sedation in most horses. Complete resolution of lesions was noted in all horses immediately post-treatment and the long-term resolution rate was 87.5%. Duration of therapy ranged from 1.5 to 8 months (median: 2.9 mean: 3.5). All horses were followed-up for 12–22 months after treatment was discontinued and only two horses had a recurrence of lesions. Clinical signs related to the aural plaques prior to treatment were reported in 11 of 16 (68.8%) horses and included resistance to touching the ears and bridling. Complete resolution of these signs was reported by the owners in all of the horses followedup for at least 12 months. In conclusion, the topical application of imiquimod 5% cream is an efficacious treatment for aural plaques in horses.

Description

This is the peer reviewed version of the following article: The efficacy of imiquimod 5% cream (Aldara ® ) in the treatment of aural plaque in horses: a pilot open‐label clinical trial Torres, Sheila M. F. ; Malone, Erin D. ; White, Stephen D. ; Koch, Sandra N. ; Watson, Johanna L. Veterinary Dermatology, October 2010, Vol.21(5), pp.503-509, which has been published in final form at https://onlinelibrary-wiley-com.ezp1.lib.umn.edu/doi/epdf/10.1111/j.1365-3164.2009.00877.x. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Related to

Replaces

License

Collections

Series/Report Number

Funding information

This project was supported by the University of Minnesota Equine Center, College of Veterinary Medicine, University of Minnesota, with funds provided by the Minnesota Racing Commission, Minnesota Agricultural Experimental Station, and contributions from private donors. Imiquimod was generously donated by 3M Pharmaceutical

Isbn identifier

Doi identifier

10.1111/j.1365-3164.2009.00877.x

Previously Published Citation

The efficacy of imiquimod 5% cream (Aldara ® ) in the treatment of aural plaque in horses: a pilot open‐label clinical trial Torres, Sheila M. F. ; Malone, Erin D. ; White, Stephen D. ; Koch, Sandra N. ; Watson, Johanna L. Veterinary Dermatology, October 2010, Vol.21(5), pp.503-509

Other identifiers

Suggested citation

Torres, Sheila MF; Malone, Erin D; White, Stephen D; Koch, Sandra N; Watson, Johanna L. (2010). The efficacy of imiquimod 5% cream (Aldara) in the treatment of aural plaque in horses: a pilot open-label clinical trial. Retrieved from the University Digital Conservancy, 10.1111/j.1365-3164.2009.00877.x.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.